Can N acetyl cysteine - Taurine provide additional reduction in microalbuminuria in type 2 diabetic patients already on optimum doses of Angiotensin converting enzyme inhibitors?

The effects of taurine supplementation on diabetes mellitus in humans: A systematic review and meta-analysis

“…The literature search identified 2206 studies, of which 471 studies were from PubMed, 37 were from the Cochrane Library, 902 were from Embase, 790 were from the Web of Science and 6 were from clinical trials. After excluding 563 duplicates, reviewing 1643 titles and abstracts, 1557 outcomes were excluded, and the remaining 86 outcomes were sought for retrival, The full text of 10 articles can not be obtained, 54 articles were assessed in detain, of which 28 studies were excluded for interventions not eligible, 16 studies were excluded for patients not eligible, 10 studies were excluded for outcomes not eligible, resulting in a total of 5 randomized controlled studies of taurine for diabetes included in the meta-analysis ( Esmaeili et al, 2021 , Moloney et al, 2010 , Premanath et al, 2019 , Samadpour Masouleh et al, 2021 , Svarovskaya and Garganeeva, 2018 ). The study selection process is summarized in the PRISMA flow chart ( Fig.…”

“…After excluding this group of data, the heterogeneity was reduced to zero, so this group of data was not included. A total of five RCTs ( Esmaeili et al, 2021 , Moloney et al, 2010 , Premanath et al, 2019 , Samadpour Masouleh et al, 2021 , Svarovskaya and Garganeeva, 2018 ), reported, in a total of 199 patients, 113 taurine users and 86 non-users, that taurine had the potential to reduce TG compared to controls (SMD −0.26 [95% CI: −0.55, 0.02], p = 0.07), but the difference was not statistically significant. There was no heterogeneity between studies (p = 0.43, I 2 = 0%) ( Fig.…”

“…A total of five RCTs ( Esmaeili et al, 2021 , Moloney et al, 2010 , Premanath et al, 2019 , Samadpour Masouleh et al, 2021 , Svarovskaya and Garganeeva, 2018 ), reported, in a total of 199 patients, 113 taurine users and 86 non-users, that taurine had the potential to reduce TC compared to controls, but the difference was not statistically significant (SMD −0.17 [95% CI: −0.46, 0.12], p = 0.24). There was no heterogeneity between studies (p = 0.41, I 2 = 0%) ( Fig.…”

“…Four RCTs ( Esmaeili et al, 2021 , Moloney et al, 2010 , Premanath et al, 2019 , Svarovskaya and Garganeeva, 2018 ) reported the HDL levels of 179 patients, 103 taurine users and 76 non-users. There was no significant difference in HDL level increase between the taurine group and the control group.…”

“…A total of five RCTs ( Esmaeili et al, 2021 , Moloney et al, 2010 , Premanath et al, 2019 , Samadpour Masouleh et al, 2021 , Svarovskaya and Garganeeva, 2018 ), reported on LDL in 219 patients, 123 taurine users and 96 non-users. Compared with the control group, taurine was more likely to reduce LDL levels, but the statistical difference was not significant (SMD −0.16 [95% CI: −0.51, 0.20], p = 0.39).…”